Grant: China-Canada Joint Health Research Initiative
McMaster University
$150,000.00
Induction of autophagic cell death: a potential therapeutic strategy against childhood AML by rapamycin and transferrin receptor antibody
FY 2008-09
Summary
The typical treatment for childhood acute myeloid leukemia
(AML) is intensive chemotherapy with several drugs that are
often toxic to patients. As a result, treatment-related death in
childhood AML remains significant problems. Furthermore, half
as many children likely to suffer relapse following standard
therapy and many of them develop resistance to subsequent
treatment with the same chemotherapeutic drugs. Thus, novel
approaches are needed to overcome the problem. We propose to
evaluate a combined therapy using two established agents that
may kill AML cells through a pathway different from the one
used by conventional chemotherapies. Since this approach is to
target a shared cell death pathway, our studies will help develop
an alternative therapy not only for childhood AML in particular,
but also for other tumors in general.
Department
Program
China-Canada Joint Health Research Initiative
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
182645
Name
Wan Yonghong
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
National Natural Science Foundation of China (Haidian, Beijing)
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Induction of autophagic cell death: a potential therapeutic strategy against childhood AML by rapamycin and transferrin receptor antibody
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
China-Canada Joint Health Research Initiative
Keyworddelim
Antibody; Autophagy; Childhood Acute Myeloid Leukemia; Rapamycin; Transferrin Receptor; Xenograft
Abstract
The typical treatment for childhood acute myeloid leukemia
(AML) is intensive chemotherapy with several drugs that are
often toxic to patients. As a result, treatment-related death in
childhood AML remains significant problems. Furthermore, half
as many children likely to suffer relapse following standard
therapy and many of them develop resistance to subsequent
treatment with the same chemotherapeutic drugs. Thus, novel
approaches are needed to overcome the problem. We propose to
evaluate a combined therapy using two established agents that
may kill AML cells through a pathway different from the one
used by conventional chemotherapies. Since this approach is to
target a shared cell death pathway, our studies will help develop
an alternative therapy not only for childhood AML in particular,
but also for other tumors in general.
Competitiondate
200903
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wan, Yonghong; Huang, Bo
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Human Dev &Child &Yth~ $150,000~ $0~